Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens

Leuk Res. 2011 Mar;35(3):301-4. doi: 10.1016/j.leukres.2010.09.002. Epub 2010 Nov 24.

Abstract

There is no standard salvage regimen for AML. We retrospectively compared two commonly used regimens at our institution: CLAG and MEC. The complete response rate (CR) was 37.9% for CLAG (n=97) and 23.8% for MEC (n=65) (P=0.048), with median overall survival (OS) of 7.3 and 4.5 months, respectively (P=0.05). In primary refractory disease, CR was 45.5% for CLAG and 22.2% for MEC (P=0.09), with median OS of 11 and 4.5 months, respectively (P=0.07). In first relapse, CR was 36.8% and 25.9% (P=0.35) and median OS was 6.7 and 6.7 months, respectively (P=0.87). Our data support use of CLAG for RR-AML.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cladribine / therapeutic use
  • Cytarabine / therapeutic use
  • Etoposide / therapeutic use
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Middle Aged
  • Mitoxantrone / therapeutic use
  • Neoplasm Recurrence, Local / drug therapy*
  • Remission Induction
  • Retrospective Studies
  • Salvage Therapy*
  • Survival Rate
  • Treatment Outcome
  • Young Adult

Substances

  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Cladribine
  • Etoposide
  • Mitoxantrone

Supplementary concepts

  • CLAG protocol
  • MAV protocol